Vasopressin Inhibits LTP in the CA2 Mouse Hippocampal Area

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Chafai, Magda ^a   Corbani, Maithé ^a   Guillon, Gilles ^a   Desarménien, Michel G ^a  

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN NERVE CELL; CONTROLLED STUDY; ELECTRIC POTENTIAL; ENTORHINAL CORTEX; EPISODIC MEMORY; HIPPOCAMPAL CA2 REGION; HORMONE ACTION; HORMONE INHIBITION; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL STIMULATION; NERVE POTENTIAL; NEUROMODULATION; NONHUMAN; PROTEIN FUNCTION; PYRAMIDAL NERVE CELL; SOCIAL BEHAVIOR; SYNAPSE; WHOLE CELL;

ANIMALS; CA2 REGION, HIPPOCAMPAL; ELECTRIC STIMULATION; EXCITATORY POSTSYNAPTIC POTENTIALS; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; PATCH-CLAMP TECHNIQUES; PYRAMIDAL CELLS; SYNAPSES; SYNAPTIC TRANSMISSION; VASOPRESSINS;

MUS;

EID: 84870858399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049708     Document Type: Article

References (42)

1. Van Wimersma Greidanus TB, De Wied D, (1980) Physiological significance of neurohypophyseal hormones in memory processes. Acta Psychiatr Belg 80: 721-727.
2. Bao AM, Meynen G, Swaab DF, (2008) The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev 57: 531-553.
3. Frank E, Landgraf R, (2008) The vasopressin system-from antidiuresis to psychopathology. Eur J Pharmacol 583: 226-242.
4. Surget A, Belzung C, (2008) Involvement of vasopressin in affective disorders. Eur J Pharmacol 583: 340-349.
5. Caldwell HK, Lee HJ, Macbeth AH, Young WS 3rd, (2008) Vasopressin: behavioral roles of an "original" neuropeptide. Prog Neurobiol 84: 1-24.
6. Donaldson ZR, Young LJ, (2008) Oxytocin, vasopressin, and the neurogenetics of sociality. Science 322: 900-904.
7. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M, (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 12: 524-538.
8. Rood BD, De Vries GJ, (2011) Vasopressin innervation of the mouse (Mus musculus) brain and spinal cord. J Comp Neurol 519: 2434-2474.
9. Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G, (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24: 580-588.
10. Barberis C, Audigier S, Johnson AE, Tribollet E, Jard S, (1993) Characterization and distribution of 125I-labeled Phaa,D-Tyr(Me),Phe,Gln,Asn,Arg,Pro,Arg,Tyr-NH2 (125I-linear AVP antagonist) binding sites in rat brain. Ann N Y Acad Sci 689: 475-476.
11. Johnson AE, Audigier S, Rossi F, Jard S, Tribollet E, et al. (1993) Localization and characterization of vasopressin binding sites in the rat brain using an iodinated linear AVP antagonist. Brain Res 622: 9-16.
12. Vaccari C, Lolait SJ, Ostrowski NL, (1998) Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology 139: 5015-5033.
13. Hernando F, Schoots O, Lolait SJ, Burbach JP, (2001) Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 142: 1659-1668.
14. Young WS, Li J, Wersinger SR, Palkovits M, (2006) The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience 143: 1031-1039.
15. Ostrowski NL, Lolait SJ, Young WS 3rd, (1994) Cellular localization of vasopressin V1a receptor messenger ribonucleic acid in adult male rat brain, pineal, and brain vasculature. Endocrinology 135: 1511-1528.
16. Murgatroyd C, Wigger A, Frank E, Singewald N, Bunck M, et al. (2004) Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety. J Neurosci 24: 7762-7770.
17. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, et al. (2002) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A 99: 6370-6375.
18. Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, et al. (2002) Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 300: 1122-1130.
19. Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ, (2004) Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 29: 483-493.
20. DeVito LM, Konigsberg R, Lykken C, Sauvage M, Young WS 3rd, et al. (2009) Vasopressin 1b receptor knock-out impairs memory for temporal order. J Neurosci 29: 2676-2683.
21. Egashira N, Tanoue A, Higashihara F, Mishima K, Fukue Y, et al. (2004) V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze. Neurosci Lett 356: 195-198.
22. Caldwell HK, Wersinger SR, Young WS 3rd, (2008) The role of the vasopressin 1b receptor in aggression and other social behaviours. Prog Brain Res 170: 65-72.
23. Wersinger SR, Caldwell HK, Martinez L, Gold P, Hu SB, et al. (2007) Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav 6: 540-551.
24. Wersinger SR, Ginns EI, O'Carroll AM, Lolait SJ, Young WS 3rd, (2002) Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry 7: 975-984.
25. Tiberiis BE, Wilson N, McLennan H, (1983) Neurohypophysial peptides and the hippocampus. I. Vasopressin immunoreactivity in the rat hippocampus. Neuropeptides 4: 65-72.
26. Sloviter RS, (1983) "Epileptic" brain damage in rats induced by sustained electrical stimulation of the perforant path. I. Acute electrophysiological and light microscopic studies. Brain Res Bull 10: 675-697.
27. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS, (1998) A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry 44: 88-97.
28. Piskorowski RA, Chevaleyre V, (2012) Synaptic integration by different dendritic compartments of hippocampal CA1 and CA2 pyramidal neurons. Cell Mol Life Sci 69: 75-88.
29. Chevaleyre V, Siegelbaum SA, (2010) Strong CA2 pyramidal neuron synapses define a powerful disynaptic cortico-hippocampal loop. Neuron 66: 560-572.
30. Bartesaghi R, Gessi T, (2004) Parallel activation of field CA2 and dentate gyrus by synaptically elicited perforant path volleys. Hippocampus 14: 948-963.
31. Mercer A, Eastlake K, Trigg HL, Thomson AM, (2010) Local circuitry involving parvalbumin-positive basket cells in the CA2 region of the hippocampus. Hippocampus.
32. Chevaleyre V, Dayanithi G, Moos FC, Desarmenien MG, (2000) Developmental regulation of a local positive autocontrol of supraoptic neurons. J Neurosci 20: 5813-5819.
33. Hamann M, Desarmenien M, Desaulles E, Bader MF, Feltz P, (1988) Quantitative evaluation of the properties of a pyridazinyl GABA derivative (SR 95531) as a GABAA competitive antagonist. An electrophysiological approach. Brain Res 442: 287-296.
34. Chen C, Diaz Brinton RD, Shors TJ, Thompson RF, (1993) Vasopressin induction of long-lasting potentiation of synaptic transmission in the dentate gyrus. Hippocampus 3: 193-203.
35. Dubrovsky B, Tatarinov A, Gijsbers K, Harris J, Tsiodras A, (2003) Effects of arginine-vasopressin (AVP) on long-term potentiation in intact anesthetized rats. Brain Res Bull 59: 467-472.
36. Sakurai E, Maeda T, Kaneko S, Akaike A, Satoh M, (1998) Inhibition by [Arg8]-vasopressin of long term potentiation in guinea pig hippocampal slice. Jpn J Pharmacol 77: 103-105.
37. Raggenbass M, (2008) Overview of cellular electrophysiological actions of vasopressin. Eur J Pharmacol 583: 243-254.
38. Tobin V, Gouty LA, Moos FC, Desarmenien MG, (2006) A store-operated current (SOC) mediates oxytocin autocontrol in the developing rat hypothalamus. European Journal of Neuroscience 24: 400-404.
39. Huber D, Veinante P, Stoop R, (2005) Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308: 245-248.
40. Kombian SB, Mouginot D, Pittman QJ, (1997) Dendritically released peptides act as retrograde modulators of afferent excitation in the supraoptic nucleus in vitro. Neuron 19: 903-912.
41. Corbani M, Trueba M, Stoev S, Murat B, Mion J, et al. (2011) Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors. J Med Chem 54: 2864-2877.
42. Zwier JM, Roux T, Cottet M, Durroux T, Douzon S, et al. (2010) A fluorescent ligand-binding alternative using Tag-lite(R) technology. J Biomol Screen 15: 1248-1259.